Literature DB >> 3770014

The effects of phenytoin dosage on the induction of alpha 1-acid glycoprotein and antipyrine clearance in the dog.

F P Abramson, M P Lutz.   

Abstract

Doses of phenytoin from 90 to 800 mg/d were used to study induction of hepatic cytochrome P-450 and plasma alpha 1-acid glycoprotein in dogs. The antipyrine clearance was increased by 80%, which is equivalent to an increase in cytochrome P-450 of 140%, and the plasma glycoprotein concentration rose 200% at the highest dose of phenytoin used. Plasma concentrations of phenytoin were measured at each dose level to provide a definitive value for the amount of inducer present. These data were used to assess the concentration-response relationship for phenytoin inducing either cytochrome P-450 or the glycoprotein. A simple relationship between concentration and effect was not observed, suggesting a complex mechanism of induction.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3770014     DOI: 10.1007/BF03189839

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  20 in total

1.  The metabolism of methylated aminoazo dyes. V. Evidence for induction of enzyme synthesis in the rat by 3-methylcholanthrene.

Authors:  A H CONNEY; E C MILLER; J A MILLER
Journal:  Cancer Res       Date:  1956-06       Impact factor: 12.701

2.  Determination of intact oxazepam by electron capture gas chromatography after an extractive alkylation reaction.

Authors:  J Vessman; M Johansson; P Magnusson; S Strömberg
Journal:  Anal Chem       Date:  1977-09       Impact factor: 6.986

3.  Kinetic models of induction: I. Persistence of the inducing substance.

Authors:  F P Abramson
Journal:  J Pharm Sci       Date:  1986-03       Impact factor: 3.534

4.  Dose-dependent enzyme induction.

Authors:  A Breckenridge; M L Orme; L Davies; S S Thorgeirsson; D S Davies
Journal:  Clin Pharmacol Ther       Date:  1973 Jul-Aug       Impact factor: 6.875

5.  Plasma diphenylhydantoin levels after loading and maintenance doses.

Authors:  B J Wilder; E E Serrano; R E Ramsay
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

6.  Effect of diphenylhydantoin on hepatic drug hydroxylation.

Authors:  F Petruch; R V Schüppel; G Steinhilber
Journal:  Eur J Clin Pharmacol       Date:  1974-07-26       Impact factor: 2.953

7.  Effect of dose on phenytoin absorption.

Authors:  D Jung; J R Powell; P Walson; D Perrier
Journal:  Clin Pharmacol Ther       Date:  1980-10       Impact factor: 6.875

8.  Antiepileptic drugs and alpha 1-acid glycoprotein.

Authors:  E Tiula; P J Neuvonen
Journal:  N Engl J Med       Date:  1982-10-28       Impact factor: 91.245

9.  The kinetics of induction by rifampin of alpha 1-acid glycoprotein and antipyrine clearance in the dog.

Authors:  F P Abramson; M P Lutz
Journal:  Drug Metab Dispos       Date:  1986 Jan-Feb       Impact factor: 3.922

10.  Interactions of phenobarbital with propranolol in the dog. 1. Plasma protein binding.

Authors:  S A Bai; F P Abramson
Journal:  J Pharmacol Exp Ther       Date:  1982-09       Impact factor: 4.030

View more
  4 in total

Review 1.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Changes in the concentration of serum alpha 1-acid glycoprotein in epileptic patients.

Authors:  K Morita; A Yamaji
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

3.  Modification of inflammatory processes by phenobarbital in rats.

Authors:  F E Levy; L Chauvelot-Moachon; I Florentin; M Forest; C Poüs; C Fournier; J P Giroud
Journal:  Inflammation       Date:  1991-12       Impact factor: 4.092

4.  The effect of induction with phenobarbital on the kinetics and bioavailability of antipyrine in the dog.

Authors:  F P Abramson
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Apr-Jun       Impact factor: 2.441

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.